OPKHealthcare · Diagnostics & ResearchThe 6 Wall Street analysts covering OPKO Health, Inc. hold a median 12-month price target of $3 — +119.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 14 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores OPKO Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (91): Sales and profits are climbing, and climbing faster than before.
Value (31): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OPK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +119.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Apr 2026 | Barrington Research | Downgrade | Market Perform | — |
| 2 Mar 2026 | Barrington Research | Maintains | Outperform | — |
| 20 Nov 2025 | JP Morgan | Initiates | Neutral | — |
| 31 Oct 2025 | Jefferies | Downgrade | Hold | — |
| 30 Oct 2025 | Barrington Research | Maintains | Outperform | — |
| 1 May 2025 | Barrington Research | Maintains | Outperform | — |
| 25 Apr 2025 | JP Morgan | Initiates | Neutral | — |
| 7 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Mar 2025 | Barrington Research | Maintains | Outperform | — |
| 12 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Feb 2025 | Barrington Research | Maintains | Outperform | — |
| 8 Jan 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Nov 2024 | Barrington Research | Maintains | Outperform | — |
| 26 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Sept 2024 | Barrington Research | Maintains | Outperform | — |
| 17 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Sept 2024 | Piper Sandler | Reiterates | Overweight | — |
| 8 Aug 2024 | Barrington Research | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OPK appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, OPKO Health, Inc. returned −9.9% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 56% of US stocks
Cheaper than 76% of US stocks
Cheaper than 88% of US stocks
Higher than 37% of US stocks
Higher than 41% of US stocks
Higher than 60% of US stocks
Higher than 22% of US stocks
Higher than 18% of US stocks
Higher than 39% of US stocks
Higher than 31% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
OPKO Health, Inc. has a market value of $985.2M and an enterprise value of $1.1B.
Revenue in the twelve months to 30 June 2026: $587.9M. The latest quarter grew 4.3% year on year.
Net income over the same four quarters: −$72.9M, a −12.4% net margin.
Diluted earnings per share, trailing twelve months: $−0.09.
Free cash flow in the twelve months to 30 June 2026: −$134.0M, after $10.6M of capital spending.
OPKO Health, Inc. spent $46.6M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −4.4×; forward P/E: −4.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
OPKO Health, Inc. employs 2,275 people — $258K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own OPKO Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks suggests retaining OPKO Health stock, citing potential growth from RAYALDEE, partner revenues, and a leaner BioReference business, while noting that pipeline and reimbursement risks remain key concerns.
Why it matters — OPK watchers would care because the article highlights both the company's growth drivers and the ongoing risks that could affect its performance.
OPKO Health's stock has risen 32.5% year-to-date in 2026, with the rally attributed to pharmaceutical growth, a broad clinical pipeline, strategic partnerships, and new non-dilutive financing.
Why it matters — A OPK watcher would care because these factors—pipeline, partnerships, and non-dilutive financing—are central drivers shaping the company's performance and share-price momentum this year.
OPKO Health outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations. Management highlighted a pipeline of early-stage clinical programs, external collaborations, and available capital to fund development over a data-rich 12-to-18-month period.
Why it matters — OPK watchers would care because the company's strategic pivot toward therapeutics and its development pipeline could shape its future business mix and direction.
OPKO Health, Inc. announced it will participate in the Wells Fargo 21st Annual Healthcare Conference. The announcement was made via press release on September 8, 2026, from Miami.
Why it matters — OPK watchers would care because the company's participation indicates it will present or engage with investors at a major healthcare industry conference.
OPKO Health (OPK) reported earnings 30 days ago, and its stock is down 9.7% since that earnings report. The item notes that the company's next move for the stock is being watched.
Why it matters — An OPK watcher would care because the stock has declined notably in the month following the latest earnings report, with attention now on what comes next for the company.
The 6 Wall Street analysts covering OPKO Health, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $8.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering OPKO Health, Inc., 4 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OPKO Health, Inc. 76 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, OPKO Health, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (91 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +119.0% from the last close, and Ticker Nerd's factor model ranks OPKO Health, Inc. 76 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering OPKO Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OPK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $8.5 over the next 12 months.
OPKO Health, Inc. returned -9.9% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
OPKO Health, Inc. is a diversified healthcare company focused on diagnostics and pharmaceuticals.
The most recent item we track (Zacks Investment Research, 28 Sept 2026): "Here's Why You Should Retain OPK Stock in Your Portfolio for Now". Zacks suggests retaining OPKO Health stock, citing potential growth from RAYALDEE, partner revenues, and a leaner BioReference business, while noting that pipeline and reimbursement risks remain key concerns.
OPKO Health, Inc. is a diversified healthcare company focused on diagnostics and pharmaceuticals. Through its Diagnostics segment, the company provides clinical laboratory and genetic testing services, including BioReference Health and specialized assays used in disease detection, monitoring, and patient management. Its Pharmaceutical segment markets approved therapies and supports development programs across areas such as kidney disease, hormone-related disorders, oncology, and infectious diseases. OPKO Health also works with commercial partners and maintains manufacturing, supply, and research activities across several international markets. The company plays a broad role in the healthcare market by combining testing services, marketed medicines, and pipeline assets within a single operating platform. OPKO Health, Inc. is headquartered in Miami, Florida.
CEO Dr. Phillip Frost M.D., Ph.D. · 2,275 employees · United States · https://www.opko.com
